The impact of VUS reclassification on reproductive decision making
PLOS One · 2025
DOI: 10.1371/journal.pone.0308771 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Alexandra Peyser und 2 weiteren Autor:innen. Beteiligte Einrichtung: Northwell, New Hyde Park, New York; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, North Shore Univ…. Hauptthemen laut MEDLINE: Decision Making, Genetic Testing, Reproduction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Laboratories will occasionally reclassify a VUS to pathogenic (P) or likely pathogenic (LP), making it clinically actionable. Here, we aim to characterize the frequency of this reclassification in genes tested routinely during preconception counseling in order to help guide reproductive decision making.
Design
Utilizing the American College of Medical Genetics (ACMG) 113-gene pre-conception panel, we conducted data analysis from ClinVar Miner ( https://clinvarminer.genetics.utah.edu/ ). The numbers of VUS’s reported for each gene were recorded over a 3-year period (2019, 2021, & 2022). In addition, data on the number of VUS’s in conflict (VUS/P and VUS/LP) were recorded. The 10 genes with the most VUS’s and the genes with the most frequent reporting discordance were compared over the 3 years, Results There was a 103% increase in the number of VUS’s reported (2019: 13,278, 2021: 22,434, 2022: 26,965) and a 235% increase in the number of VUS’s in conflict (2019:387, 2021: 946, 2022:1297). The overall percent conflict increased significantly (2019: 2.9% vs. 2022: 4.8%). Nine genes among the top 10 with the most frequent VUS’s remained the same over the 3-year period, while five out of the ten most frequent genes with VUS’s in conflict remained the same.
Conclusions
The rate of conflicting reporting of a VUS has increased in 3 years and is currently at 4.8%. A potential upgrade of a VUS to pathogenic or likely pathogenic may turn the variant “actionable,” justifying testing embryos for the variant through PGT-M.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Northwell, New Hyde Park, New York; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, North Shore University Hospital, Manhasset, New York; Zucker School of Medicine, Union…
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States of America.
- Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Renaissance School of Medicine, Stony Brook University Hospital, Stony Brook, New York, United States of America.
ORCID-Profile: Alexandra Peyser
Zitieren
APA
Peyser, A., Onel, K., & Hershlag, A. (2025). The impact of VUS reclassification on reproductive decision making. PLOS One. https://doi.org/10.1371/journal.pone.0308771
Vancouver
Peyser A, Onel K, Hershlag A. The impact of VUS reclassification on reproductive decision making. PLOS One. 2025. doi:10.1371/journal.pone.0308771
BibTeX
@article{Peyser2025,
author = {Peyser, Alexandra and Onel, Kenan and Hershlag, Avner},
title = {The impact of VUS reclassification on reproductive decision making},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0308771}
}
EUVIMED